Extranodal NK-T-cell lymphoma diagnostic study of choice

	Extranodal NK-T-cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Extranodal NK-T-cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Xray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Extranodal NK-T-cell lymphoma diagnostic study of choice On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Extranodal NK-T-cell lymphoma diagnostic study of choice All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Extranodal NK-T-cell lymphoma diagnostic study of choice
CDC on Extranodal NK-T-cell lymphoma diagnostic study of choice
Extranodal NK-T-cell lymphoma diagnostic study of choice in the news
Blogs on Extranodal NK-T-cell lymphoma diagnostic study of choice
Risk calculators and risk factors for Extranodal NK-T-cell lymphoma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Diagnostic Study of Choice

Study of choice

Investigations:

Pathological examination of frozen section specimen may be misled the NK/T cell diagnosis.^[1]
Circulating cell free EBV DNA levels by RT-PCR is a diagnostic factor for EBV assosiated malignancies^[2], Like extranodal/NK T cell lymphoma.^[3]
Measuring both Bam HI W DNA and LMP1 DNA is more useful as a prognosis predictor, these DNAs will decrease with treatment and increase with relapse.^[4]
Recently, determination of negative immune checkpoints are considered as a drug target^[5],in the case of extranodal NK/T cell lymphoma, PD-L1 will be expressed in the tumor, and patients with higher concenteration of soluble PD-L1 showed worse prognosis.^[6]

Diagnostic results

The accompaniment of following findings on performing immunophenotyping on frozen section specimen and RT-PCR are confirmatory for Extranodal NK/T cell lymphoma:

Detection of CD56 and EBER1 on tumor cells^[7]
EBV DNA (RT-PCR)^[2]

References

↑ Harabuchi, Yasuaki; Takahara, Miki; Kishibe, Kan; Nagato, Toshihiro; Kumai, Takumi (2019). "Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress". Frontiers in Pediatrics. 7. doi:10.3389/fped.2019.00141. ISSN 2296-2360.
↑ ^2.0 ^2.1 Harabuchi, Yasuaki; Imai, Shosuke; Wakashima, Junichi; Hirao, Motoyasu; Kataura, Akikatsu; Osato, Toyoro; Kon, Shinichiro (1996). "Nasal T-cell lymphoma causally associated with Epstein-Barr virus: Clinicopathologic, phenotypic, and genotypic studies". Cancer. 77 (10): 2137–2149. doi:10.1002/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.0.CO;2-V. ISSN 0008-543X.
↑ Lei, Kenny I. K.; Chan, Lisa Y.S.; Chan, Wing Y.; Johnson, Philip J.; Lo, Y. M. Dennis (2000). "Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies". British Journal of Haematology. 111 (1): 239–246. doi:10.1046/j.1365-2141.2000.02344.x. ISSN 0007-1048.
↑ Ishii, Hideyuki; Ogino, Takeshi; Berger, Christoph; Köchli-Schmitz, Nicole; Nagato, Toshihiro; Takahara, Miki; Nadal, David; Harabuchi, Yasuaki (2007). "Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T-cell lymphoma". Journal of Medical Virology. 79 (5): 562–572. doi:10.1002/jmv.20853. ISSN 0146-6615.
↑ Taube, J. M.; Klein, A.; Brahmer, J. R.; Xu, H.; Pan, X.; Kim, J. H.; Chen, L.; Pardoll, D. M.; Topalian, S. L.; Anders, R. A. (2014). "Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy". Clinical Cancer Research. 20 (19): 5064–5074. doi:10.1158/1078-0432.CCR-13-3271. ISSN 1078-0432.
↑ Nagato, Toshihiro; Ohkuri, Takayuki; Ohara, Kenzo; Hirata, Yui; Kishibe, Kan; Komabayashi, Yuki; Ueda, Seigo; Takahara, Miki; Kumai, Takumi; Ishibashi, Kei; Kosaka, Akemi; Aoki, Naoko; Oikawa, Kensuke; Uno, Yuji; Akiyama, Naoko; Sado, Masatoshi; Takei, Hidehiro; Celis, Esteban; Harabuchi, Yasuaki; Kobayashi, Hiroya (2017). "Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy". Cancer Immunology, Immunotherapy. 66 (7): 877–890. doi:10.1007/s00262-017-1987-x. ISSN 0340-7004.
↑ Harabuchi, Yasuaki; Takahara, Miki; Kishibe, Kan; Moriai, Shigetaka; Nagato, Toshihiro; Ishii, Hideyuki (2009). "Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features". International Journal of Clinical Oncology. 14 (3): 181–190. doi:10.1007/s10147-009-0882-7. ISSN 1341-9625.

Template:WH Template:WS

[HarabuchiTakahara2019-1] Harabuchi, Yasuaki; Takahara, Miki; Kishibe, Kan; Nagato, Toshihiro; Kumai, Takumi (2019). "Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress". Frontiers in Pediatrics. 7. doi:10.3389/fped.2019.00141. ISSN 2296-2360.

[HarabuchiImai1996-2] 2.0 ^2.1 Harabuchi, Yasuaki; Imai, Shosuke; Wakashima, Junichi; Hirao, Motoyasu; Kataura, Akikatsu; Osato, Toyoro; Kon, Shinichiro (1996). "Nasal T-cell lymphoma causally associated with Epstein-Barr virus: Clinicopathologic, phenotypic, and genotypic studies". Cancer. 77 (10): 2137–2149. doi:10.1002/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.0.CO;2-V. ISSN 0008-543X.

[LeiChan2000-3] Lei, Kenny I. K.; Chan, Lisa Y.S.; Chan, Wing Y.; Johnson, Philip J.; Lo, Y. M. Dennis (2000). "Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies". British Journal of Haematology. 111 (1): 239–246. doi:10.1046/j.1365-2141.2000.02344.x. ISSN 0007-1048.

[IshiiOgino2007-4] Ishii, Hideyuki; Ogino, Takeshi; Berger, Christoph; Köchli-Schmitz, Nicole; Nagato, Toshihiro; Takahara, Miki; Nadal, David; Harabuchi, Yasuaki (2007). "Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T-cell lymphoma". Journal of Medical Virology. 79 (5): 562–572. doi:10.1002/jmv.20853. ISSN 0146-6615.

[TaubeKlein2014-5] Taube, J. M.; Klein, A.; Brahmer, J. R.; Xu, H.; Pan, X.; Kim, J. H.; Chen, L.; Pardoll, D. M.; Topalian, S. L.; Anders, R. A. (2014). "Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy". Clinical Cancer Research. 20 (19): 5064–5074. doi:10.1158/1078-0432.CCR-13-3271. ISSN 1078-0432.

[NagatoOhkuri2017-6] Nagato, Toshihiro; Ohkuri, Takayuki; Ohara, Kenzo; Hirata, Yui; Kishibe, Kan; Komabayashi, Yuki; Ueda, Seigo; Takahara, Miki; Kumai, Takumi; Ishibashi, Kei; Kosaka, Akemi; Aoki, Naoko; Oikawa, Kensuke; Uno, Yuji; Akiyama, Naoko; Sado, Masatoshi; Takei, Hidehiro; Celis, Esteban; Harabuchi, Yasuaki; Kobayashi, Hiroya (2017). "Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy". Cancer Immunology, Immunotherapy. 66 (7): 877–890. doi:10.1007/s00262-017-1987-x. ISSN 0340-7004.

[HarabuchiTakahara2009-7] Harabuchi, Yasuaki; Takahara, Miki; Kishibe, Kan; Moriai, Shigetaka; Nagato, Toshihiro; Ishii, Hideyuki (2009). "Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features". International Journal of Clinical Oncology. 14 (3): 181–190. doi:10.1007/s10147-009-0882-7. ISSN 1341-9625.

[1]

[2]

[3]

[4]

[5]

[6]

[7]